| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 25, 2012Study Results Slated for Presentation in Late-Breaking Clinical Trials Session at Endocrinology Meeting Include Low Event Rates Through Two Years of Follow-Up
MINNEAPOLIS--(BUSINESS WIRE)--May. 25, 2012-- According to study results to be featured in Sunday’s late-breaking clinical trials session at the American Association of Clinical Endocrinologists...
-
May 22, 2012Revenue of $4.3 Billion Grew 4% on a Constant Currency Basis; 3% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--May. 22, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year ended April 27, 2012. The company reported...
-
May 17, 2012Rigorous Trial Design and Monitoring Provides New Insight to Outcomes for Men and Women with Aortic Stenosis
PARIS--(BUSINESS WIRE)--May. 17, 2012-- Medtronic, Inc. (NYSE: MDT) today announced new results from the Medtronic CoreValve ADVANCE Study, which found that women and men benefitted similarly from...
-
May 16, 2012New Randomized Controlled Trial Results Presented At EuroPCR Demonstrate Clinical Advantages Favoring Drug-Eluting Balloons Over Uncoated Balloons and Stents
PARIS--(BUSINESS WIRE)--May. 16, 2012-- Physicians presented today at EuroPCR 2012 the results of two multicenter, randomized controlled trials, the BELLO and PACIFIER studies, each one showing...
-
May 16, 2012Randomized Controlled Trial Results Presented At EuroPCR Demonstrate Advantages Over Uncoated Angioplasty Balloons and Drug-Eluting Stents
PARIS--(BUSINESS WIRE)--May. 16, 2012-- Please replace the release with the following corrected version due to multiple revisions. The corrected release reads: MEDTRONIC IN.PACT DRUG-ELUTING...
-
May 15, 2012
MINNEAPOLIS--(BUSINESS WIRE)--May. 15, 2012-- Medtronic (NYSE: MDT) will host an institutional investor and analyst meeting on Friday, June 1, 2012, in New York City from 9:00 a.m. to...
-
May 10, 2012
MINNEAPOLIS--(BUSINESS WIRE)--May. 10, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the fourth quarter and fiscal year 2012 on Tuesday, May 22, 2012. A...
-
Apr 27, 2012Six Month Pooled Outcomes From Randomized and Crossover Patients Following Renal Denervation Presented at the 22nd Annual Scientific Meeting of the European Society of Hypertension Confirm Previous Symplicity Clinical Trial Findings
MINNEAPOLIS & LONDON, Apr 27, 2012 (BUSINESS WIRE) --Medtronic, Inc., (NYSE: MDT), announced today six month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical...
-
Mar 26, 2012ACC.12 Late-breaker Shows Promise of Pacemakers through Diminishing Fainting Recurrences in Patients Diagnosed with Syncope
MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 26, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered...
-
Mar 25, 2012Data from Two Clinical Trials Presented at the 61st Annual Scientific Session of the American College of Cardiology Show Consistent Effectiveness and Safety Up to Three Years
MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 25, 2012-- Medtronic, Inc. (NYSE:MDT), announced that the Symplicity™ renal denervation system provides safe, significant and sustained blood...
-
Mar 24, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 24, 2012-- Medtronic, Inc. (NYSE: MDT) today announced results from its largest international, prospective, single-arm clinical trial evaluating the Medtronic...
-
Mar 24, 2012Recently FDA-Approved, Novel Heart Device Shows Consistently Low Event Rates Across Broad Spectrum of Coronary Artery Disease Patients, Including Those with Diabetes
CHICAGO--(BUSINESS WIRE)--Mar. 24, 2012-- According to new clinical data presented today at ACC.12 –– the 61st Annual Scientific Session & Expo of the American College of Cardiology (ACC)...
-
Mar 1, 2012“Global Heroes” Will Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 1, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it is recruiting runners from around the world who benefit from medical technology to participate in the...
-
Feb 29, 2012World’s First Insulin Pump with Low Glucose Suspend Showed Reduces Time Spent in Low Threshold Range
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 29, 2012-- In the next step toward the development of an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced that the results of the in-clinic ASPIRE...
-
Feb 21, 2012Revenue of $3.9 Billion Driven by International Revenue Growth of 6% on a Constant Currency Basis, 7% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 21, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2012, which ended January 27, 2012. The company...
-
Feb 17, 2012Distinguished by Superior Deliverability and Diabetes Indication, New Heart Device Becomes Available to Cath Labs Nationwide
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 17, 2012-- Advancing the clinical practice of interventional cardiovascular medicine, Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (
-
Feb 10, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 10, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the third quarter of its fiscal year 2012 on Tuesday, February 21,...
-
Feb 8, 2012New Clinical Data Presented for First Time at Medical Meetings in U.S. and Europe Show Durable Vessel Patency in Treating Atherosclerotic Lesions of Superficial Femoral Artery
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 8, 2012-- Consistent with its commitment to developing better treatments for peripheral arterial disease (PAD), Medtronic Inc. (NYSE:MDT) today announced the...
-
Jan 24, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 24, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the first patient was enrolled in the FIRE AND ICE clinical trial, which is a prospective, randomized,...
-
Dec 10, 2011
MINNEAPOLIS, Nov 10, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the second quarter of its fiscal year 2012 on Tuesday, November 22,...
-
Dec 9, 2011Neurostimulator with Innovative Motion Sensor Technology Was Recently Approved by the FDA for the Management of Chronic Pain
MINNEAPOLIS--(BUSINESS WIRE)--Dec. 9, 2011-- Clinical trial data presented at the 15th Annual Meeting of the North American Neuromodulation Society demonstrate the AdaptiveStim™ with...
-
Nov 20, 2011Revenue of $4.1 Billion Grew 3% on a Constant Currency Basis, 6% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 22, 2011-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2012, which ended October 28, 2011. The company...
-
Nov 17, 2011
MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--Nov. 17, 2011-- Medtronic, Inc. (NYSE:MDT) and Bain Capital, a leading global private investment firm, today announced they have entered into a definitive...
-
Nov 17, 2011Neurostimulator Uses Innovative Motion Sensor Technology to Provide Patient Comfort and Convenience
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 17, 2011-- Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food & Drug Administration (FDA) approval of its AdaptiveStim™ with RestoreSensor™...
-
Nov 9, 2011Study Will Evaluate Accuracy of Latest Innovation to Help People with Diabetes Improve Glucose Control
MINNEAPOLIS, Nov 09, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced a new United States investigational device exemption study to evaluate the accuracy of six-day use in...